These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 36358716)

  • 1. Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review.
    Guo Y; Xiang D; Wan J; Yang L; Zheng C
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
    Sacdalan DB; Lucero JA; Sacdalan DL
    Onco Targets Ther; 2018; 11():955-965. PubMed ID: 29503570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictability of Neutrophile to Lymphocyte Ratio and Platelet to Lymphocyte Ratio on the Effectiveness of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer patients: A Meta-Analysis.
    Nguyen CTT; Van TNK; Huong PT
    Cancer Control; 2024; 31():10732748241285474. PubMed ID: 39285591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen X; Meng F; Jiang R
    Front Oncol; 2021; 11():746976. PubMed ID: 34900692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang S; Qiu C; Yu H; Xu Y; Xu X
    Front Oncol; 2023; 13():1070019. PubMed ID: 37143942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
    Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
    Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy.
    Viñal D; Gutierrez-Sainz L; Martinez D; Garcia-Cuesta JA; Pedregosa J; Villamayor J; Ostios L; Sanchez-Cabrero D; Higuera O; Pinto A; Rodriguez-Salas N; Espinosa E; de Castro J; Feliu J
    Clin Transl Oncol; 2021 Jun; 23(6):1185-1192. PubMed ID: 33226553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
    Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
    BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of neutrophil-to-lymphocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Li LL; Pan LS
    Kaohsiung J Med Sci; 2023 Aug; 39(8):842-852. PubMed ID: 37166079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis.
    Jin J; Yang L; Liu D; Li W
    BMJ Open; 2020 Jun; 10(6):e035031. PubMed ID: 32499266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
    Leng J; Wu F; Zhang L
    Front Oncol; 2022; 12():734948. PubMed ID: 35651788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
    Kawada T; Yanagisawa T; Mostafaei H; Sari Motlagh R; Quhal F; Rajwa P; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pallauf M; Pradere B; Teoh JY; Karakiewicz PI; Araki M; Shariat SF
    Eur Urol Focus; 2023 Mar; 9(2):264-274. PubMed ID: 36774273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.
    Petrelli F; Ghidini M; Ghidini A; Tomasello G
    JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Han CL; Meng GX; Ding ZN; Dong ZR; Chen ZQ; Hong JG; Yan LJ; Liu H; Tian BW; Yang LS; Xue JS; Li T
    Front Immunol; 2022; 13():827788. PubMed ID: 35211122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Rugambwa TK; Abdihamid O; Zhang X; Peng Y; Cai C; Shen H; Zeng S; Qiu W
    Front Oncol; 2023; 13():1181248. PubMed ID: 38023176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.